Bile Duct Cancer, also known as cholangiocarcinoma, begins in the biliary system and depending on where the cancer exactly affects the bile ducts, it may be categorized as intrahepatic, extrahepatic, hilar, and distal. The bile duct originates in the liver and is a 4-5 inch tube that connects the liver/gallbladder to the small intestine. Extrahepatic bile cancer occurs when the cancer affects the bile duct outside the liver. Bile duct cancer is very rare with a low survival rate of around 30% for five years for individuals diagnosed with early stage bile duct cancer. Treatment options for cholangiocarcinoma include surgery, chemotherapy, radiation therapy, and alternative options. There are four stages of bile duct cancer that define its progression and location, which will inevitably determine treatment plans and strategy.
Top Research Reagents
We have 7411 products for the study of Biliary Tract Cancer that can be applied to Chromatin Immunoprecipitation (ChIP), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot from our catalog of antibodies and ELISA kits.